AT 342

Drug Profile

AT 342

Alternative Names: AAV-gene-therapy-Audentes; AAV-UGT1A1; AT-342; Crigler-Najjar-Syndrome-gene-therapy-Audentes

Latest Information Update: 15 Mar 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Audentes Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; Myotubularin expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperbilirubinaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hyperbilirubinaemia

Most Recent Events

  • 01 Feb 2017 Preclinical trials in Hyperbilirubinaemia in USA (unspecified route)
  • 01 Feb 2017 US FDA approves IND application for AT 342 in Hyperbilirubinaemia
  • 12 Dec 2016 AT 342 receives Orphan Drug status for Hyperbilirubinaemia in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top